Xeris is a biopharmaceutical company in Chicago that sells medicines for rare endocrine and neurological diseases. XERS reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 6 | Barclays | Target raised | Buy | |
| Sep 10 | Leerink Partners | Maintained | Buy | |
| Aug 20 | Barclays | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in XERS in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XERS is in one of them and how their past XERS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered XERS in an article yet. Here's the latest on the wider market.
About Xeris Biopharma Holdings
Xeris is a biopharmaceutical company based in Chicago, Illinois, that develops and sells medicines for chronic endocrine and neurological diseases in the United States. Its marketed products include Recorlev for Cushing's syndrome, Gvoke, a glucagon treatment for severe low blood sugar, and Keveyis for primary periodic paralysis. Its customers include patients and the clinicians who treat them, and it is developing a weekly injectable form of levothyroxine for hypothyroidism.
- Headquarters
- Chicago, IL